FCH
GILD icon

Freestone Capital Holdings’s Gilead Sciences GILD Stock Holding History

Freestone Capital Holdings’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,000
Closed -$72K – 357
2016
Q4 		$72K Buy
+1,000
New +$74.3K 0.01% 342
2016
Q3 		– Sell
-3,500
Closed -$292K – 345
2016
Q2 		$292K Buy
+3,500
New +$311K 0.03% 289

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Freestone Capital Holdings's GILD Position: Q1 2026 in Review

Freestone Capital Holdings increased its Gilead Sciences (GILD) stake by 0.2% in Q1 2026, buying an estimated $2.38K and bringing the position to 8,650 shares worth $1.21M. The position accounts for 0.04% of the portfolio, ranked #220.

Freestone Capital Holdings first reported a position in GILD in Q2 2013 and has held it in 49 quarters since. The position peaked at $24.9M in Q3 2018. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Freestone Capital Holdings held 8,650 shares of Gilead Sciences worth $1.21M as of Q1 2026.
  • Freestone Capital Holdings bought 17 Gilead Sciences shares in Q1 2026, an estimated $2.38K.
  • Gilead Sciences made up 0.04% of Freestone Capital Holdings's portfolio in Q1 2026, its #220 holding.
  • Freestone Capital Holdings first reported a position in Gilead Sciences in Q2 2013 and has held it in 49 quarters since.
  • Freestone Capital Holdings's Gilead Sciences position peaked at $24.9M in Q3 2018.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Freestone Capital Holdings's 13F filing for Q1 2026, filed 13 May 2026.